Dermata Therapeutics Inc
NASDAQ:DRMA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Dermata Therapeutics Inc
NASDAQ:DRMA
|
US |
|
Z
|
Zhejiang JW Precision Machinery Co Ltd
SZSE:300984
|
CN |
|
Shenzhen Energy Group Co Ltd
SZSE:000027
|
CN |
|
E
|
Enel Americas SA
SGO:ENELAM
|
CL |
|
Zanyu Technology Group Co Ltd
SZSE:002637
|
CN |
|
Kenmare Resources PLC
LSE:KMR
|
IE |
|
O
|
Ober SA
PAR:ALOBR
|
FR |
|
CapitaLand Ascott Trust
OTC:ATTRF
|
SG |
|
Saudi Investment Bank SJSC
SAU:1030
|
SA |
Dermata Therapeutics Inc
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. The company is headquartered in San Diego, California and currently employs 8 full-time employees. The company went IPO on 2021-08-13. The firm focuses on the treatment of medical and aesthetic skin conditions. Its lead product candidate, DMT310, is a product candidate, which is developed from its Spongilla technology platform. DMT310 is a topical product derived from sourced freshwater sponge with multiple components. Its DMT310 is under clinical development for the treatment of acne vulgaris (acne), psoriasis vulgaris (psoriasis), and papulopustular rosacea (rosacea). The Company’s Spongilla technology platform is based on the use of a naturally growing freshwater sponge, Spongilla lacustris (Spongilla). Spongilla is a freshwater sponge that grows in rivers and lakes in commercial quantities in select regions of the world, such as the northern hemisphere. Its clinical development pipeline consists of DMT310 and DMT410.
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. The company is headquartered in San Diego, California and currently employs 8 full-time employees. The company went IPO on 2021-08-13. The firm focuses on the treatment of medical and aesthetic skin conditions. Its lead product candidate, DMT310, is a product candidate, which is developed from its Spongilla technology platform. DMT310 is a topical product derived from sourced freshwater sponge with multiple components. Its DMT310 is under clinical development for the treatment of acne vulgaris (acne), psoriasis vulgaris (psoriasis), and papulopustular rosacea (rosacea). The Company’s Spongilla technology platform is based on the use of a naturally growing freshwater sponge, Spongilla lacustris (Spongilla). Spongilla is a freshwater sponge that grows in rivers and lakes in commercial quantities in select regions of the world, such as the northern hemisphere. Its clinical development pipeline consists of DMT310 and DMT410.
